Key result
Bifurcation angioplasty with DES maintains 24-month stent patency without restenosis in severe pulmonary vein stenosis.
Why the study?
Does bifurcation angioplasty with drug-eluting stents improve stent patency and symptoms in a patient with severe pulmonary vein stenosis post-AF ablation?
Case Report (n=1)
Does bifurcation angioplasty with drug-eluting stents improve stent patency and symptoms in a patient with severe pulmonary vein stenosis post-AF ablation?
Bifurcation angioplasty using drug-eluting stents may be an effective and durable treatment for severe pulmonary vein stenosis following atrial fibrillation ablation.
Answers are grounded in this paper and cite their sources.
May support DES bifurcation stenting as durable option for severe post-ablation PVS; leaves open need for prospective validation before practice change.
A 53-year-old man with long-standing persistent AF underwent multiple ablation procedures. A presentation with hemoptysis led to a left pulmonary artery wedge angiography and thoracic computed tomography (CT) scan, which revealed a tight bifurcation stenosis of the left superior pulmonary vein (LSPV). This was treated by angioplasty with drug-eluting stents to avoid restenosis by bare-metal stent implantation in small diameter PVs as already described. After predilatation, two 4 × 32-mm and a 3 × 20-mm Taxus® Liberté stents (Boston Scientific, Natick, MA, USA) were deployed across upper and lower LSPV branches and the ostio-antral segment. Twenty-two month follow-up CT angiography showed patent stents in the LSPV, without in-stent restenosis (no arrhythmia or hemoptysis at 24-month follow-up).
No takes yet. Share an insight, caveat, or question.
Jariwala et al. (2012) conducted a case report in Post-AF ablation severe pulmonary vein stenosis (n=1). Bifurcation angioplasty using drug-eluting stents was evaluated on In-stent restenosis, arrhythmia, or hemoptysis at follow-up. Bifurcation angioplasty using drug-eluting stents successfully treated severe pulmonary vein stenosis, with patent stents and no restenosis, arrhythmia, or hemoptysis at 24-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: